Jianxun Qi | Vaccine Development | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Jianxun Qi | Vaccine Development | Research Excellence Award

 Chinese Academy of Sciences | China

Dr. Jianxun Qi is an eminent professor at the Institute of Microbiology, Chinese Academy of Sciences (IMCAS), renowned for his groundbreaking contributions to structural virology and host–pathogen interaction research. As a leading scientific innovator, he has focused extensively on defining the molecular mechanisms governing how viruses recognize and invade host cells, with influential work spanning influenza viruses, coronaviruses, filoviruses, and other emerging pathogens. Dr. Qi’s expertise in structural biology and protein chemistry has enabled him to decode complex viral architectures and receptor engagements that underpin infection and cross-species transmission.His research has produced a series of landmark discoveries published in prestigious journals. Among his most notable works are Structural Basis of H7N9 Influenza Virus Receptor Binding (Science), Receptor Specificity of H6N6 Influenza Virus (EMBO), Structural Insights into MERS-CoV Receptor Engagement (Nature), and Architecture of SARS-CoV-2 Spike–ACE2 Interaction (Cell). Dr. Qi has also made major contributions to understanding Ebola virus, Thogotovirus, African Swine Fever Virus, Coxsackievirus A10, and SFTSV, detailed through influential publications in Cell, PNAS, and Nature Communications. His studies have provided essential molecular frameworks that support the development of vaccines, therapeutic antibodies, and antiviral strategies worldwide.

Citation Metrics (Scopus)

20000

15000

10000

5000

0

Citations
18,928

Documents
294

h-index
67

Citations
Documents
h-index


View Scopus Profile

Featured Publications

Moutih Rafei | Vaccine Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Moutih Rafei | Vaccine Development | Best Researcher Award

Full Professor at Université de Montréal | Canada

Dr. Moutih Rafei is a Full Professor at Université de Montréal specializing in pharmacology, immunology, and molecular biology. He is internationally recognized for his pioneering work in T-cell development, cell therapy, cytokine biology, and vaccine engineering. As founder and CEO of Axiom Services Inc., and former CSO of multiple biotech companies, he bridges academic innovation with industry translation. His career includes over 60 peer-reviewed publications, six patents, and leadership in high-impact immuno-oncology projects. Dr. Rafei is a sought-after keynote speaker, scientific advisor, and grant reviewer, contributing significantly to advancing novel therapeutic platforms for cancer, infectious diseases, and immune system modulation.

Publication Profile 

Google Scholar

Education

Dr. Rafei earned his B.Sc. Honours in Immunology from McGill University, completing a thesis on Giardia lamblia DNA vaccine design. He pursued a PhD in Experimental Medicine at McGill under Dr. Jacques Galipeau, focusing on fusokine-based immunosuppression strategies. He then completed a postdoctoral fellowship at Université de Montréal with Dr. Claude Perreault, studying innate and classical CD8 T-cell development. Complementing his scientific expertise, Dr. Rafei completed the Mini-Entrepreneurship Program at HEC-Poly-UdeM, gaining business strategy training. His multidisciplinary education combines deep immunological research skills with innovation management, positioning him at the intersection of cutting-edge biomedical science, translational medicine, and biotech entrepreneurship.

Experience 

Dr. Rafei’s professional experience spans academia and industry. In academia, he is a Full Professor at Université de Montréal, leading translational hemato-oncology research and mentoring over 60 trainees. In industry, he founded Axiom Services Inc. and co-founded IntelliStem Technologies Inc., guiding R&D in T-cell and stem cell therapies. He served as Chief Scientific Officer for Defense Therapeutics Inc. and IntelliStem, and as Head of Discovery at Medicenna Therapeutics, advancing IL-2 superkine programs to clinical trials. He has presented at major international conferences, secured over $6.5 million in research funding, and consulted for biotech and pharma companies, bridging scientific discovery and product development.

Awards and Honors 

Dr. Rafei has received numerous prestigious awards recognizing his research excellence and leadership. These include the Science Features Excellence Award, recognition among the Most Influential Healthcare Leaders to Watch, and Canada’s Most Visionary Men Leaders in Healthcare. He earned the AAI-Life Technologies Trainee Achievement Award, American Society of Hematology Travel Awards, and the Cedarlane Greenberg Award. His work has been ranked among the Quebec and earned multiple competitive fellowships, including CIHR, Terry Fox Foundation, and FRSQ. He has also been nominated for national innovation awards, consistently  in peer-reviewed competitions and gaining international recognition for scientific impact.

Research Focus 

Dr. Rafei’s research integrates immunology, cell therapy, and biotechnology to develop next-generation therapeutic strategies. His expertise includes T-cell development, cytokine and chemokine biology, fusokine engineering, hematopoietic stem cell transplantation, and vaccine design. He applies high-throughput screening for small-molecule discovery and engineers DNA-, peptide-, protein-, and cell-based vaccines. His current work emphasizes mesenchymal stromal cell platforms (ARM-X) for cancer immunotherapy, immune-oncology drug development, and novel approaches for infectious disease prevention. By combining basic immunology with translational application, Dr. Rafei aims to generate safe, effective, and customizable therapies to treat cancer and modulate immune responses in diverse clinical contexts.

Publication Top Notes

Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner

Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction

Cell therapy: types, regulation, and clinical benefits

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis

Nociceptor neurons affect cancer immunosurveillance

A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties

Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR 2

Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome

Mesenchymal stem cells beyond regenerative medicine

An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis

Hassan Yarmohammadi | Vaccine Development | Best Researcher Award

Published on by Top Pharmaceutical

Hassan Yarmohammadi | Vaccine Development | Best Researcher Award

Mr. Hassan Yarmohammadi, Tehran Paramedical School, Iran

Dr. Hassan Yarmohammadi holds a B.Sc. in Laboratory Science and earned his M.Sc. and Ph.D. in Microbiology. With over 25 years in medical and molecular diagnostics and five years of research experience, he specializes in vaccine development. His Ph.D. thesis focused on creating a dual vaccine candidate using rotavirus VP8 and hepatitis A virus VP1 proteins. He has published research in IJM and Vaccine Research journals. Passionate about innovation in microbial immunology, Dr. Yarmohammadi continues to contribute to translational science and public health.

Publication Profile

Scopus

Education

Mr. Hassan Yarmohammadi holds a distinguished academic background with a degree in [insert specific degree] 🎓, specializing in [insert field of study]. With extensive experience in both teaching and research, he has contributed significantly to [insert relevant industry or academic discipline] 📚. Throughout his professional journey, Mr. Yarmohammadi has published numerous articles in reputable journals and actively participated in national and international conferences 🌍. His dedication to academic excellence and continuous learning has earned him several accolades 🏆. Committed to innovation and knowledge sharing, he continues to inspire students and colleagues alike through his impactful work and professional leadership 💼.

Professional Memberships

Mr. Hassan Yarmohammadi is an active member of several prestigious professional organizations that reflect his commitment to excellence and collaboration in his field 🤝. He holds memberships in [insert organization names, e.g., the International Society of [Your Field] 🌐, the National Association of [Your Profession] 🏛️], and other leading societies that promote research, innovation, and professional development 📈. Through these affiliations, he engages with a global network of experts, participates in conferences, and contributes to advancing industry standards 🌟. His involvement underscores his dedication to staying current with the latest trends and fostering meaningful connections within the professional community 💼.

Research Focus

Mr. Hassan Yarmohammadi specializes in vaccine development 🧬💉, focusing on creating innovative and effective vaccines using cutting-edge techniques such as reverse vaccinology 🔬 and immunoinformatics 💻🧫. His recent work involves designing a novel bivalent vaccine candidate targeting both hepatitis A virus 🦠 and rotavirus 🤢, aiming to improve global health through enhanced immunization strategies. By integrating computational biology with immunology, Hassan contributes to faster and more precise vaccine discovery, addressing viral diseases that significantly impact public health worldwide 🌍. His research bridges molecular biology, bioinformatics, and vaccinology to combat infectious diseases.

Publication Top Notes

Development of a novel bivalent vaccine candidate against hepatitis A virus and rotavirus using reverse vaccinology and immunoinformatics